Medicine enterprise document management method, device and system and storage medium
Through the server automation, the approval process and nodes are determined, and the inefficiency and compliance problems in pharmaceutical company document management are solved, the full process automation is realized, the approval efficiency and accuracy are improved, and the operation is reduced. Cost and compliance risks.
Patent Information
- Application Number
- CN202411225980.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-09-03
AI Technical Summary
The existing technology traditional Chinese medicine companies have low document management efficiency, poor version control, cumbersome approval process, and serious information silos, which have affected the efficiency and compliance of document management, increasing operating costs and compliance risks.
Obtain the draft of pharmaceutical companies' documents and information through the server, determine the approval process and nodes, realize the automated approval process, and start the training process based on the approval results, and finally convert the draft into a formal document to realize the automation of the entire process.
It significantly improves approval efficiency and accuracy, ensures the accuracy and compliance of decisions, reduces human errors, and improves work efficiency and transparency in document management.
Smart Images

Figure CN119090446A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical enterprise document management, and in particular to a pharmaceutical enterprise document management method, device, system and storage medium. Background Art
[0002] In pharmaceutical companies, the management of regulations and workflow documents is a key link to ensure compliance and efficiency of corporate operations. These documents not only involve the internal management of the company, but are also directly related to product quality and patient safety. With the rapid development of the pharmaceutical industry and the continuous updating of regulations, the complexity and importance of document management are increasing.
[0003] In the existing technology, file management mainly relies on traditional paper documents and manual operations. The drafting, approval, distribution, and archiving of documents are mostly done manually, which is inefficient. File version control is difficult, the approval process is cumbersome, and the problem of information islands is prominent. These are common problems in the existing technology. For example, the constant revision of documents makes it a challenge to maintain the consistency and traceability of different versions, and it is difficult to ensure that all users use the latest version of the document. The traditional paper approval process is time-consuming and inefficient, and the communication during the approval process is not smooth, resulting in delays.
[0004] The defects of existing technologies in document management are mainly manifested in the following aspects: poor document version control, cumbersome approval process, serious information island problem, inadequate training management, untimely document distribution, inconvenient document archiving and retrieval, imperfect review mechanism, low efficiency in document drafting and revision, high legal compliance risk, inconvenient borrowing management, difficulty in cross-departmental collaboration, and strong dependence on technical systems. These problems not only affect the efficiency and accuracy of document management, but also increase the operating costs and compliance risks of enterprises.
[0005] The defects of document management are also manifested in the following aspects: First, the poor control of document versions may lead to different users using different versions of documents, affecting the consistency of decision-making and execution. Second, the approval process is cumbersome and time-consuming, which affects the timely update and application of documents. Third, the problem of information islands leads to poor information sharing between different departments, increasing the risk of duplication of work and errors. In addition, the training management is not in place, and employees do not understand the new policies well, which affects the implementation effect of the policies. The untimely distribution of documents leads to the failure to timely communicate the updated documents to all relevant personnel, affecting the normal development of work. The inconvenience of document archiving and retrieval increases the difficulty of finding and using documents. The imperfect review mechanism leads to the continued use of outdated documents, increasing compliance risks. The inefficiency of document drafting and revision increases the workload of document management. The risk of legal compliance is high, and improper document management may cause legal problems. The inconvenience of borrowing management affects the efficiency of document utilization. The difficulty of cross-departmental collaboration increases the coordination cost of document management. The strong dependence on technical systems increases the impact of system failures or upgrades on document management. The existence of these problems has seriously affected the efficiency and effectiveness of document management in pharmaceutical companies, and it is urgent to improve and optimize. Summary of the invention
[0006] In a first aspect, the present invention provides a method for managing pharmaceutical enterprise documents, comprising:
[0007] The service end obtains the pharmaceutical company document draft and the corresponding document information, and determines the corresponding approval process and approval node according to the document information, so that the approval end can approve the pharmaceutical company document draft according to the approval process based on the approval node;
[0008] The server receives the approval result of the approval end based on the approval node;
[0009] If the approval result is approved, the server determines the corresponding training process and training unit according to the document information, so as to train the training unit according to the training process;
[0010] The server receives the training result information of the training unit, and converts the draft pharmaceutical enterprise document into a corresponding formal pharmaceutical enterprise document according to the training result information.
[0011] In an optional implementation manner, before receiving the approval result of the approval node, the method further includes:
[0012] The approval end obtains the document information and the approval process, and obtains the corresponding approval part in the pharmaceutical enterprise document draft according to the approval process and the document information;
[0013] The approval end approves the approval part to obtain the approval result.
[0014] In an optional implementation manner, the approval end approves the approval part to obtain the approval result, including:
[0015] The approval end obtains content information corresponding to each analysis unit in the approval part, and confirms corresponding keywords according to the content information; wherein the content information includes at least one of text information and graphic information;
[0016] The approval end matches the corresponding regulatory clause information of each level according to the keywords; wherein the regulatory clause information includes departmental laws, administrative regulations, local regulations, departmental rules and enterprise standards;
[0017] Determining whether the content information corresponding to the analysis unit complies with all the regulatory clause information;
[0018] If so, determining compliance of the content information corresponding to the analysis unit, and generating prompt information of compliance with laws and regulations, so as to prompt the approval end to approve and generate the approval result;
[0019] If not, the non-compliant regulatory clauses will be listed and non-compliant prompt information will be generated to prompt the approval end to approve and generate the approval result.
[0020] In an optional implementation manner, the approval end matches the corresponding regulatory clause information of each level according to the keyword, including:
[0021] Constructing a semantic matching model and a database of regulatory clauses; wherein the semantic matching model includes keyword vectors corresponding to keywords and regulatory clause vectors; the regulatory clause data includes index information corresponding to each regulatory clause;
[0022] Based on the semantic matching model, the similarity between the keyword vector and the regulatory clause vector is calculated; wherein the similarity calculation method includes:
[0023]
[0024] similarity represents the similarity; A represents the keyword vector; B represents the regulatory clause vector; A·B represents the dot product of the keyword vector and the regulatory clause vector; ‖A‖ and ‖B‖ represent the Euclidean norm of the keyword vector and the regulatory clause vector;
[0025] The similarities are screened according to a preset threshold, and regulatory clause information of various levels matching the keywords is obtained through the regulatory clause database.
[0026] In an optional implementation manner, the approval end approves the approval part, further comprising:
[0027] Cutting the approval part into a plurality of grid units connected in sequence; and setting a membership function for each of the grid units;
[0028] Monitor the mouse movement event, and obtain the current position of the mouse hovering according to the movement event;
[0029] Calculating the center distance between the current position of the mouse and the geometric center of each of the grid cells;
[0030] Calculating the membership value of each grid unit according to the center distance;
[0031] According to the membership value, the fuzziness of the grid unit is set; and according to the fuzziness, the display effect of each grid unit is set.
[0032] In an optional implementation, the method for calculating the center distance includes:
[0033]
[0034] Wherein, d represents the center distance; (x mouse -x center ) represents the current coordinates of the mouse; (y mouse -y center ) represents the coordinates of the geometric center of the grid cell.
[0035] In an optional implementation, the method for calculating the membership value includes:
[0036]
[0037] Wherein, d represents the center distance; σ represents the control coefficient of the fuzziness; and e represents the membership value.
[0038] In a second aspect, the present invention provides a management device for pharmaceutical enterprise documents, comprising:
[0039] A determination module is used for the server to obtain the pharmaceutical company document draft and the corresponding document information, and determine the corresponding approval process and approval node according to the document information, so that the approval end can approve the pharmaceutical company document draft according to the approval process based on the approval node;
[0040] A receiving module, used for the server to receive the approval result of the approval end based on the approval node;
[0041] The determination module is further configured to, if the approval result is approved, determine the corresponding training process and training unit according to the document information by the server, so as to train the training unit according to the training process;
[0042] A generation module is used for the server to receive the training result information of the training unit, and convert the draft pharmaceutical enterprise document into a corresponding formal pharmaceutical enterprise document according to the training result information.
[0043] In a third aspect, the present invention provides a management system for pharmaceutical company documents, comprising a memory and a processor, wherein the memory stores a management program for pharmaceutical company documents, and the processor runs the management program for pharmaceutical company documents so that the management system for pharmaceutical company documents executes a management method for pharmaceutical company documents as described in any one of the aforementioned embodiments.
[0044] In a fourth aspect, the present invention provides a computer-readable storage medium, on which a pharmaceutical company document management program is stored. When the pharmaceutical company document management program is executed by a processor, the pharmaceutical company document management method as described in any one of the aforementioned implementation modes is implemented.
[0045] The present invention provides a management method for pharmaceutical company documents, including: the service end obtains the pharmaceutical company document draft and the corresponding document information, and determines the corresponding approval process and approval node according to the document information, so that the approval end approves the pharmaceutical company document draft based on the approval node according to the approval process; the service end receives the approval result of the approval end based on the approval node; if the approval result is approved, the service end determines the corresponding training process and training unit according to the document information, so as to train the training unit according to the training process; the service end receives the training result information of the training unit shown, and converts the pharmaceutical company document draft into the corresponding pharmaceutical company formal document according to the training result information. In an optional implementation, before receiving the approval result of the approval node, it also includes: the approval end obtains the document information and the approval process, and, according to the approval process and the document information, obtains the corresponding approval part in the pharmaceutical company document draft; the approval end approves the approval part and obtains the approval result.
[0046] The present invention establishes a structured approval process by automatically acquiring and processing draft documents and their information through the server, thereby significantly improving the approval efficiency and accuracy. The approval end quickly locates and approves the key parts of the document according to the established process, ensuring the accuracy and compliance of the decision. In addition, once the approval is passed, the server immediately starts a customized training process to conduct targeted training for relevant personnel to further ensure the standardization and effectiveness of document execution. Finally, the server automatically completes the conversion of the draft document to the formal document based on the training results, realizing the full process automation of document management, reducing human errors, and improving overall work efficiency and transparency of document management. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] In order to more clearly illustrate the technical solution of the present invention, the following is a brief introduction to the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present invention and should not be regarded as limiting the scope of protection of the present invention. In each of the drawings, similar components are numbered similarly.
[0048] Figure 1 It is a structural diagram of the hardware operating environment involved in the embodiment of the pharmaceutical enterprise document management method of the present invention;
[0049] Figure 2 This is a flow chart of Example 1 of the method for managing pharmaceutical enterprise documents of the present invention;
[0050] Figure 3 This is a supplementary flow chart before step S200 in Example 2 of the method for managing pharmaceutical enterprise documents of the present invention;
[0051] Figure 4 This is a schematic diagram of a detailed process of step S600 (including steps S610 to S650) in Example 2 of the management method for pharmaceutical enterprise documents of the present invention;
[0052] Figure 5 This is a schematic diagram of a detailed process of step S620 in Example 2 of the method for managing pharmaceutical enterprise documents of the present invention;
[0053] Figure 6 This is a schematic diagram of a detailed process of step S600 (including steps S660-1 to S660-4) in Example 3 of the management method for pharmaceutical enterprise documents of the present invention;
[0054] Figure 7 Schematic diagram of module connections of a device for managing pharmaceutical company documents in an embodiment of the present invention. DETAILED DESCRIPTION
[0055] The embodiments of the present invention are described in detail below, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions.
[0056] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. In the description of the present invention, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.
[0057] In the present invention, unless otherwise clearly specified and limited, the terms "installed", "connected", "connected", "fixed" and the like should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection or an indirect connection through an intermediate medium, it can be the internal connection of two elements or the interaction relationship between two elements. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.
[0058] It should be understood that the specific embodiments described herein are only used to explain the present invention, and are not used to limit the present invention.
[0059] like Figure 1 , which is a schematic diagram of the structure of the hardware operating environment of the terminal involved in the embodiment of the present invention.
[0060] The management system of pharmaceutical enterprise documents provided in the embodiment of the present invention can be a PC, or a mobile terminal device such as a smart phone, a tablet computer or a portable computer. The management system of the pharmaceutical enterprise documents may include: a processor 1001, such as a CPU, a network interface 1004, a user interface 1003, a memory 1005 and a communication bus 1002. Among them, the communication bus 1002 is used to realize the connection and communication between these components. The user interface 1003 may include a display screen, an input unit such as a keyboard, and a remote control, and the optional user interface 1003 may also include a standard wired interface and a wireless interface. The network interface 1004 may optionally include a standard wired interface and a wireless interface (such as a WI-FI interface). The memory 1005 may be a high-speed RAM memory or a stable memory, such as a disk memory. The memory 1005 may also be a storage device independent of the aforementioned processor 1001. Optionally, the management system of pharmaceutical enterprise documents may also include an RF (Radio Frequency) circuit, an audio circuit, a WiFi module, and the like. In addition, the pharmaceutical company's document management system can also be configured with other sensors such as gyroscopes, barometers, hygrometers, thermometers, infrared sensors, etc., which will not be repeated here.
[0061] Those skilled in the art will understand that Figure 1The pharmaceutical enterprise document management system shown in the figure does not constitute a limitation thereof, and may include more or fewer components than shown in the figure, or combine certain components, or arrange the components differently. Figure 1 As shown, the memory 1005 as a computer-readable storage medium may include an operating system, a data interface control program, a network connection program, and a pharmaceutical company document management program.
[0062] Example 1
[0063] Reference Figure 2 Embodiment 1 of the present invention provides a method for managing pharmaceutical enterprise documents, including:
[0064] Step S100, the server obtains the pharmaceutical company document draft and corresponding document information, and determines the corresponding approval process and approval node according to the document information, so that the approval end approves the pharmaceutical company document draft based on the approval node according to the approval process;
[0065] The above-mentioned pharmaceutical enterprise documents may include, but are not limited to: rules and regulations and workflow documents, for example:
[0066] Standard Management Document (SMP): involves the company's quality objectives and policies, the responsibilities and authorities of each department / position in the organization, working relationships and communication methods, such as management procedures for plant and facilities, equipment, materials and products, confirmation and verification, production, quality control and quality assurance.
[0067] Technical Standard Documents (TS): including quality standard documents for raw materials, auxiliary materials, packaging materials, semi-finished products, intermediates, finished products, etc., as well as product process procedures, product inspection procedures, verification procedures, etc.
[0068] Standard Operating Procedures (SOPs): documents that guide employees to complete specific operations, such as job operating procedures, equipment operation, cleaning and maintenance procedures, etc.
[0069] The above method can be applied to the server and the clients of each node connected to the server.
[0070] The server starts the first step of the document management process by collecting the drafts and related information of the pharmaceutical company documents.
[0071] The draft pharmaceutical company document is a draft submitted by the applicant for pharmaceutical company documents, which is used for approval and internal training through the process.
[0072] Document draft refers to the draft document to be approved. Document information may include document type (SOP, TS, etc.), content summary, creator, creation time, etc. In this way, the basic data of the document is obtained, laying the foundation for the subsequent approval process. Ensure that the approval end has sufficient information for approval, and improve the accuracy and efficiency of approval.
[0073] As mentioned above, based on the document information, the corresponding approval process and each approval node of the approval can be determined. Based on the document information, the server determines the process and key approval nodes required for document approval. The approval process refers to the order of approval steps, and the approval node refers to the key decision point in the approval process. Clarify the approval path to ensure that the approval work is carried out in an orderly manner. Provide clear approval guidance to reduce approval time and avoid approval confusion.
[0074] The approval end can then approve the document draft according to the approval process and nodes provided by the server. The approval end may include multiple approvers, each of whom approves or modifies the document according to his or her own responsibilities.
[0075] Step S200, the server receives the approval result of the approval end based on the approval node;
[0076] As mentioned above, the server receives the approval result from the approval end as the basis for the next operation.
[0077] The approval result may be approved, rejected or other status (such as modified, conditionally approved, etc.). Obtaining formal feedback on the approval provides decision support for subsequent processing of the document and ensures real-time update and accuracy of the document status.
[0078] Step S300, if the approval result is approved, the server determines the corresponding training process and training unit according to the document information, so as to train the training unit according to the training process;
[0079] If the approval result is passed, the server will determine the training process and training unit based on the document information.
[0080] The training process refers to the steps and plans of the training, and the training unit refers to the department or personnel who need to receive training. Ensure that the relevant personnel have a full understanding of the content of the document and improve execution efficiency. Enhance the pertinence and effectiveness of the training.
[0081] Step S400, the server receives the training result information of the training unit, and converts the draft pharmaceutical enterprise document into a corresponding formal pharmaceutical enterprise document according to the training result information.
[0082] The server receives the training result information from the training unit and converts the draft document into a formal document based on the result. The conversion process may include format adjustment, version update, stamping, etc. to complete the formalization of the document and make it formally effective. Ensure that the final version of the document is accurate and can be officially released and used.
[0083] In summary, this embodiment establishes a structured approval process by automatically acquiring and processing draft documents and their information through the server, thereby significantly improving the approval efficiency and accuracy. The approval end quickly locates and approves the key parts of the document according to the established process, ensuring the accuracy and compliance of the decision. In addition, once the approval is passed, the server immediately starts a customized training process to conduct targeted training for relevant personnel to further ensure the standardization and effectiveness of document execution. Finally, the server automatically completes the conversion of the draft document to the formal document based on the training results, realizing the full process automation of document management, reducing human errors, and improving overall work efficiency and transparency of document management.
[0084] Example 2
[0085] Reference Figure 3 Embodiment 2 of the present invention provides a method for managing pharmaceutical enterprise documents. Based on the above embodiment 1, the step S200, before receiving the approval result of the approval node, further includes:
[0086] Step S500, the approval end obtains the document information and the approval process, and obtains the corresponding approval part in the pharmaceutical enterprise document draft according to the approval process and the document information;
[0087] As mentioned above, the approval end (the individual with approval authority, operating through his / her own client or system) first needs to obtain the relevant information and approval process of the document. The document information may include the type, title, content, version, author, etc. of the document, and the approval process specifies the order and steps of the approval.
[0088] The approval end obtains all the information required for approval, which helps the approver to fully understand the document content and approval requirements and ensure the accuracy of the approval.
[0089] Specifically, the document management system can provide an access interface to document information and approval processes.
[0090] Step S600: the approval end approves the approval part to obtain the approval result.
[0091] The reviewer determines the parts of the document that require special attention and approval based on the review process and document information. This may involve specific chapters, clauses, or key points of content. By focusing on the key parts of the document, the reviewer can review more efficiently and ensure that key information is fully reviewed.
[0092] For further reference, Figure 4 In step S600, the approval end approves the approval part and obtains the approval result, including:
[0093] Step S610, the approval end obtains content information corresponding to each analysis unit in the approval part, and confirms corresponding keywords according to the content information; wherein the content information includes at least one of text information and graphic information;
[0094] As mentioned above, the approval end needs to extract the content information of each analysis unit from the approval part of the draft document. The analysis unit can be a paragraph, a data table, a chart, etc. in the document, which is the basic unit that the approval end needs to focus on.
[0095] By focusing on the key analysis units of the document, the approval end can conduct a more detailed review to ensure the accuracy and completeness of the document content. Through the structured function of the document management system, each analysis unit in the document can be identified.
[0096] For example, the system can automatically identify titles, subtitles, tables, charts, etc. in a document and provide them as separate analysis units to the approval end.
[0097] As described above, the approval end identifies and confirms keywords based on the content information of the analysis unit. Keywords are the core of the document content and help the approval end quickly grasp the key points of the document.
[0098] The confirmation of keywords will help the approval side to match regulatory clauses in subsequent steps, thereby improving the pertinence and efficiency of approval.
[0099] Text analysis techniques, such as natural language processing (NLP), can be used to automatically identify and extract keywords.
[0100] For example, using text mining algorithms such as TF-IDF or topic modeling, keywords are extracted from each unit of analysis.
[0101] Step S620, the approval end matches the corresponding regulatory clause information of each level according to the keyword; wherein the regulatory clause information includes departmental laws, administrative regulations, local regulations, departmental rules and enterprise standards;
[0102] As mentioned above, the approval end matches the corresponding regulatory clause information based on the extracted keywords. This step is to ensure that the document content complies with the requirements of laws and regulations.
[0103] It should be noted that pharmaceutical company documents are the management documents, technical documents, and standard documents of pharmaceutical companies. Among these documents, such as the pharmaceutical company's technical standard operating procedures (SOP) documents must comply with laws, relevant judicial interpretations, regulations, local regulations and other requirements.
[0104] The SOP documents of pharmaceutical companies need to comply with relevant drug management laws and regulations, such as the Drug Administration Law, to ensure the legality of the drug production process.
[0105] GMP (Good Manufacturing Practice) is the international standard for drug production and quality management. Pharmaceutical company SOP documents must comply with GMP standards to ensure product quality and safety.
[0106] Different regions may have specific regulatory requirements, and pharmaceutical companies' SOP documents need to take into account the special requirements of local regulations to ensure compliance in specific regions.
[0107] In addition to laws and regulations, pharmaceutical companies are also required to follow industry guidelines and best practices, which may be issued by professional organizations or regulatory agencies.
[0108] In some cases, judicial interpretations may provide guidance on specific issues of drug production and quality management, and pharmaceutical company SOP documents need to take these interpretations into account to avoid legal risks.
[0109] Laws, regulations and industry standards may be updated and changed, and pharmaceutical company SOP documents need to be reviewed and updated regularly to ensure continued compliance.
[0110] SOP documentation should include risk management measures to ensure that potential risks are identified, evaluated and controlled during the drug production process.
[0111] Regulatory agencies may impose specific requirements on the development and implementation of pharmaceutical companies' SOP documents, and pharmaceutical companies need to meet these requirements to pass regulatory review.
[0112] In short, the technical SOP documents of pharmaceutical companies are important documents to ensure the quality and safety of drugs, and must fully comply with the requirements of laws, regulations and industry standards. This is not only a mandatory requirement of laws and regulations, but also a manifestation of corporate social responsibility.
[0113] In the above steps, when the approval is conducted at the approval end, the legality review is first conducted. Matching the regulatory terms information helps to identify potential compliance risks in the document and ensure the legality of the document.
[0114] Search keywords in the regulatory database to find relevant regulatory clauses.
[0115] For example, by building a regulatory database, the approval end can search by keywords to retrieve all relevant regulatory clauses.
[0116] Step S630, determining whether the content information corresponding to the analysis unit complies with all the regulatory clause information;
[0117] As described above, the approval end determines whether the content of the analysis unit fully complies with regulatory requirements based on the matched regulatory clause information.
[0118] Compliance judgment is a key step in the approval process, ensuring that the content of the document does not violate laws and regulations and reduce the legal risks of the enterprise. It can be judged through manual review or automated compliance checking tools. For example, the approval end can compare and analyze the unit content with the regulations, or use compliance checking software to automatically evaluate the compliance of the content.
[0119] Step S640: If yes, determine the compliance of the content information corresponding to the analysis unit, and generate prompt information of compliance with laws and regulations, so as to prompt the approval end to approve and generate the approval result;
[0120] Step S650: If not, the non-compliant regulatory clauses are listed and non-compliant prompt information is generated to prompt the approval end to approve and generate the approval result.
[0121] As mentioned above, based on the results of the compliance judgment, the approval end generates corresponding prompt information. If the content is compliant, a compliance prompt information is generated; if the content is not compliant, the non-compliant regulations are listed and a non-compliant prompt information is generated.
[0122] The prompt information provides the approval side with clear approval basis, speeding up the approval decision-making process.
[0123] Generate prompt information through the automated feedback mechanism of the approval system.
[0124] For example, the system can automatically generate prompt information based on the results of the compliance check and display it to the approval end user.
[0125] The above steps are further refinements of the document approval process, especially in terms of compliance checks. Through keyword extraction, regulatory clause matching, and compliance judgment, this step ensures the legality and compliance of the document content. The implementation of these steps can rely on modern text analysis technology and regulatory database query tools, as well as automated compliance checking software. The combined use of these technologies can greatly improve the efficiency and accuracy of pharmaceutical company document approval.
[0126] For further reference, Figure 5In step S620, the approval end matches the corresponding regulatory clause information of each level according to the keyword, including:
[0127] Step S621, constructing a semantic matching model and a regulatory clause database; wherein the semantic matching model includes a keyword vector corresponding to a keyword and a regulatory clause vector; and the regulatory clause data includes index information corresponding to each regulatory clause;
[0128] In the above, a model is created to compare the similarity between document keywords and regulatory clauses, as well as a database containing regulatory clause information. This model will help the approval end understand the relationship between document content and regulatory clauses.
[0129] By building a semantic matching model, the correlation between keywords in documents and regulatory clauses can be more accurately identified. The regulatory clause database provides a comprehensive source of regulatory information to ensure the comprehensiveness and accuracy of approvals.
[0130] Use natural language processing technology to build a semantic matching model, and use the database management system to build a regulatory terms database.
[0131] For example, machine learning algorithms are used to train semantic matching models, while regulatory clauses are digitized and stored in a database, and each clause should have corresponding index information.
[0132] Step S622: Based on the semantic matching model, the similarity between the keyword vector and the regulatory clause vector is calculated; wherein the similarity calculation method includes:
[0133]
[0134] similarity represents the similarity; A represents the keyword vector; B represents the regulatory clause vector; A·B represents the dot product of the keyword vector and the regulatory clause vector; ‖A‖ and ‖B‖ represent the Euclidean norm of the keyword vector and the regulatory clause vector;
[0135] As mentioned above, the keywords and regulatory clauses in the document are converted into vector form and the similarity between them is calculated. This step is to evaluate the matching degree between the document content and the regulatory clauses in a quantitative way. Conger obtains a quantitative similarity index to help the approval end quickly identify the consistency between the document content and the regulatory clauses.
[0136] The similarity can be calculated using the vector space model and the cosine similarity formula.
[0137] For example, use word embedding techniques such as Word2Vec or BERT to convert keywords and regulatory terms into vectors, and then apply the cosine similarity formula to calculate the similarity between them.
[0138] Formula 1 provides a standardized method to measure the similarity between two vectors, so that the approval end can compare the degree of matching between different documents and regulatory clauses. The calculation of cosine similarity is implemented through programming.
[0139] For example, in Python, we use the NumPy library to calculate the dot product and norm of the vectors, and then apply the above formula to get the similarity.
[0140] Step S623, screening the similarities according to a preset threshold, and obtaining regulatory clause information of various levels matching the keyword through the regulatory clause database.
[0141] As mentioned above, a preset threshold is set, and only when the similarity exceeds this threshold is the document content considered to match the regulatory terms.
[0142] Filter out the regulatory clauses that are highly relevant to the keywords in the document, reduce the number of regulatory clauses that need to be considered by the approval end, and improve the approval efficiency. This can be achieved by setting a threshold and filtering the similarity calculation results.
[0143] For example, if the threshold is set to 0.8, only regulatory clauses with a similarity higher than 0.8 will be considered to match the keyword and require further review by the approval end.
[0144] The steps in this embodiment are a deepening of the regulatory compliance check in the document approval process. By building a semantic matching model and a regulatory clause database, calculating the similarity between keywords and regulatory clauses, and screening according to thresholds, this step ensures the regulatory compliance of the document content. To implement these steps, existing natural language processing technology and database management technology, as well as machine learning algorithms, can be used to improve the degree of automation and accuracy. The combined use of these technologies can greatly improve the efficiency and compliance of pharmaceutical company document approval.
[0145] Example 3
[0146] Reference Figure 6 Embodiment 3 of the present invention provides a method for managing pharmaceutical enterprise documents. Based on the above embodiment 1, in step S600, the approval end approves the approval part, and further includes:
[0147] Step S660-1, cutting the approval part into a plurality of grid units connected in sequence; and setting a membership function for each of the grid units.
[0148] The confidentiality of pharmaceutical company documents during the review process is extremely important because these documents usually contain the company's business secrets and technical secrets, such as R&D information, experimental data, production processes, formulas, technical secrets, marketing strategies, sales data, customer lists, financial data, patented technologies, etc. Confidentiality not only protects the legitimate rights and interests of the company and maintains fair competition in the market, but also ensures the quality and safety of drugs. In addition, document management that complies with GMP (Good Manufacturing Practice) requirements is the key to ensuring that the entire drug production process continues to meet legal requirements.
[0149] In addition to security measures such as encryption and decryption, pharmaceutical companies also need to consider anti-voyeurism strategies during the review process, mainly to protect sensitive information on multiple levels. First, encryption technology is mainly aimed at confidentiality during data storage and transmission, while anti-voyeurism strategies increase protection during document use and display, preventing unauthorized personnel from obtaining sensitive information through visual means. Secondly, regulatory standards such as GMP require pharmaceutical companies to ensure the security and integrity of documents and data. Anti-voyeurism technology, as an additional security measure, helps meet these strict compliance requirements.
[0150] In addition, internal personnel may become a risk of information leakage, and anti-voyeurism strategies can effectively reduce the risk of sensitive information leakage due to negligence or intentional behavior. Improving employees' security awareness is also an important aspect of implementing anti-voyeurism strategies, which helps to create a more cautious and safe working atmosphere throughout the enterprise. With the development of information technology, the integration of multiple security measures including anti-voyeurism technology can enhance the innovation and effectiveness of pharmaceutical document management systems.
[0151] Conventional technologies generally only involve encryption and decryption of documents, but do not consider the problem of anti-peeping of pharmaceutical company document warehouses during the review process. In the embodiment of the present application, in order to solve the above problem, an anti-peeping strategy for pharmaceutical company document drafts during the review process is provided.
[0152] In the above, the approval part of the document is first divided into multiple small grid units, each unit represents a part of the document, which can be a paragraph of text or a part of a chart. Through grid processing, each small part of the document can be approved and analyzed more carefully. Specifically, the document content can be divided into grid units through document processing software or a custom algorithm.
[0153] For example, for text, you can divide the content into a grid based on paragraphs or sentences; for charts, you can divide it according to different parts of the chart or data points.
[0154] As described above, a membership function is set for each grid cell, and a membership function is defined, which is used to evaluate the display clarity of the cell when the mouse hovers over it.
[0155] The membership function helps to dynamically adjust the display effect of each grid unit to achieve the anti-peeping function. Specifically, a membership function can be associated with each grid unit through programming.
[0156] For example, the membership function may be a Gaussian function that adjusts the membership value based on the distance of the mouse hover position from the center of the grid cell.
[0157] Step S660-2, monitoring a mouse movement event, and obtaining a current position of the mouse hovering according to the movement event;
[0158] As described above, event monitoring technology is used to capture the movement of the mouse on the document and obtain the current position of the mouse. The mouse position is obtained in real time so that the corresponding grid unit can be processed to enhance the user experience.
[0159] Monitor mouse events through front-end scripting languages such as JavaScript.
[0160] For example, use the mousemove event listener to track the mouse position.
[0161] Step S660-3, calculating the center distance between the current position of the mouse and the geometric center of each of the grid cells;
[0162] In the above, the distance between the position of the mouse pointer and the center point of each grid unit is calculated. The distance value thus obtained will be used to determine the input of the membership function, thereby affecting the display effect of the grid unit.
[0163] Step S660-4, calculating the membership value of each of the grid cells according to the center distance;
[0164] As mentioned above, the membership function and center distance are used to calculate the membership value of each grid cell. The membership value reflects the clarity that the grid cell should display when the mouse hovers over it.
[0165] Substitute the calculated distance value into the membership function.
[0166] For example, if the membership function is a Gaussian function, substitute the distance value to obtain the membership value.
[0167] Step S660-5, setting the fuzziness of the grid unit according to the membership value; and setting the display effect of each grid unit according to the fuzziness.
[0168] As described above, the fuzziness of each grid unit is adjusted according to the membership value. The higher the membership value, the lower the fuzziness. This achieves a dynamic fuzzy effect and protects the document content from unauthorized viewing.
[0169] Specifically, the blur can be adjusted through CSS filters or graphics processing libraries.
[0170] For example, use the CSS filter:blur(value); property, where value is determined according to the membership value.
[0171] In the above, the display effect of each grid unit on the screen is finally adjusted according to the blurriness. Only the grid unit where the mouse is hovering is displayed clearly, and other units are blurred to achieve an anti-peeping effect.
[0172] You can create blur effects by dynamically adjusting the CSS properties of each grid cell or using a graphics library.
[0173] For example, set different CSS classes for each grid cell and dynamically switch these classes according to the membership value to achieve a blur effect.
[0174] The steps in this embodiment are to enhance the protection of visual information in the document approval process. Through grid processing, setting of membership function, monitoring of mouse events and dynamic adjustment of fuzziness, this step ensures the security of document content during the approval process. These steps can be implemented using front-end development technologies such as HTML, CSS and JavaScript, as well as mathematical calculations and natural language processing technologies. The combined use of these technologies can greatly improve the security and user experience of pharmaceutical company document approval.
[0175] Furthermore, the method for calculating the center distance includes:
[0176]
[0177] Wherein, d represents the center distance; (x mouse -x center ) represents the current coordinates of the mouse; (y mouse -y center ) represents the coordinates of the geometric center of the grid cell.
[0178] The above formula calculates the distance between the mouse hover position and the center of each grid cell in the document, which is the basis for implementing the anti-peeping function. The mathematical formula is used to calculate the Euclidean distance between the current coordinates of the mouse and the coordinates of the center of each grid cell, thereby obtaining the specific distance value between the mouse and the center of each grid cell.
[0179] Formula 2 can accurately reflect the position of the mouse relative to the document content, providing a basis for blur setting.
[0180] The calculation of coordinate distances can be implemented programmatically, for example using JavaScript in a web environment.
[0181] Furthermore, the method for calculating the membership value includes:
[0182]
[0183] Wherein, d represents the center distance; σ represents the control coefficient of the fuzziness; and e represents the membership value.
[0184] As described above, the membership value of each grid cell is calculated based on the center distance to determine the display clarity of the cell. The membership value f(d) is calculated based on the center distance d using a Gaussian function, which is a common membership function used in fuzzy logic, thereby obtaining the membership value of each grid cell based on its distance from the mouse position. The higher the membership value, the more important or relevant the cell is.
[0185] Formula 3 achieves the effect of dynamically adjusting the document content display according to the mouse position, thereby enhancing the document's anti-peeping capability.
[0186] For further reference, Figure 7 In an embodiment of the present application, a management device for pharmaceutical enterprise documents is also provided, including:
[0187] The determination module 10 is used for the server to obtain the pharmaceutical company document draft and the corresponding document information, and determine the corresponding approval process and approval node according to the document information, so that the approval end can approve the pharmaceutical company document draft according to the approval process based on the approval node;
[0188] A receiving module 20, configured for the server to receive the approval result of the approval end based on the approval node;
[0189] The determination module 10 is further configured to, if the approval result is approved, determine the corresponding training process and training unit according to the document information by the server, so as to train the training unit according to the training process;
[0190] The generating module 30 is used for the server to receive the training result information of the training unit, and convert the draft pharmaceutical enterprise document into a corresponding formal pharmaceutical enterprise document according to the training result information.
[0191] Furthermore, an embodiment of the present application also provides a management system for pharmaceutical company documents, including a memory and a processor, wherein the memory stores a management program for pharmaceutical company documents, and the processor runs the management program for pharmaceutical company documents so that the management system for pharmaceutical company documents executes the management method for pharmaceutical company documents as described in any of the aforementioned embodiments.
[0192] Furthermore, a computer-readable storage medium is provided in an embodiment of the present application, on which a pharmaceutical company document management program is stored. When the pharmaceutical company document management program is executed by a processor, the pharmaceutical company document management method as described in any of the aforementioned implementation methods is implemented.
[0193] In several embodiments provided in the present application, it should be understood that the disclosed devices and methods can also be implemented in other ways. The device embodiments described above are merely schematic. For example, the flowcharts and structure diagrams in the accompanying drawings show the possible architecture, functions and operations of the devices, methods and computer program products according to multiple embodiments of the present invention. In this regard, each box in the flowchart or block diagram can represent a module, a program segment or a part of a code, and the module, a program segment or a part of a code contains one or more executable instructions for implementing the specified logical function. It should also be noted that in an alternative implementation, the functions marked in the box can also occur in a different order from the order marked in the accompanying drawings. For example, two consecutive boxes can actually be executed substantially in parallel, and they can sometimes be executed in the opposite order, depending on the functions involved. It should also be noted that each box in the structure diagram and / or the flow chart, and the combination of boxes in the structure diagram and / or the flow chart, can be implemented with a dedicated hardware-based system that performs a specified function or action, or can be implemented with a combination of dedicated hardware and computer instructions.
[0194] In addition, the functional modules or units in the various embodiments of the present invention may be integrated together to form an independent part, or each module may exist independently, or two or more modules may be integrated to form an independent part.
[0195] If the functions are implemented in the form of software function modules and sold or used as independent products, they can be stored in a computer-readable storage medium. Based on this understanding, the technical solution of the present invention, or the part that contributes to the prior art or the part of the technical solution, can be embodied in the form of a software product, which is stored in a storage medium and includes several instructions for a computer device (which can be a smart phone, a personal computer, a server, or a network device, etc.) to perform all or part of the steps of the methods described in each embodiment of the present invention. The aforementioned storage medium includes: various media that can store program codes, such as a USB flash drive, a mobile hard disk, a read-only memory (ROM), a random access memory (RAM), a magnetic disk or an optical disk.
[0196] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. A method for managing pharmaceutical company documents. It is characterized in that include: The service end obtains the pharmaceutical company document draft and the corresponding document information, and determines the corresponding approval process and approval node according to the document information, so that the approval end can approve the pharmaceutical company document draft according to the approval process based on the approval node; The server receives the approval result of the approval end based on the approval node; If the approval result is approved, the server determines the corresponding training process and training unit according to the document information, so as to train the training unit according to the training process; The server receives the training result information of the training unit, and converts the draft pharmaceutical enterprise document into a corresponding formal pharmaceutical enterprise document according to the training result information.
2. The method for managing pharmaceutical enterprise documents as claimed in claim 1, It is characterized in that Before receiving the approval result of the approval node, the method further includes: The approval end obtains the document information and the approval process, and obtains the corresponding approval part in the pharmaceutical enterprise document draft according to the approval process and the document information; The approval end approves the approval part to obtain the approval result.
3. The method for managing pharmaceutical enterprise documents as claimed in claim 2, It is characterized in that The approval end approves the approval part and obtains the approval result, including: The approval end obtains content information corresponding to each analysis unit in the approval part, and confirms corresponding keywords according to the content information; wherein the content information includes at least one of text information and graphic information; The approval end matches the corresponding regulatory clause information of each level according to the keywords; wherein the regulatory clause information includes departmental laws, administrative regulations, local regulations, departmental regulations and enterprise standards, etc. Determining whether the content information corresponding to the analysis unit complies with all the regulatory clause information; If so, determining compliance of the content information corresponding to the analysis unit, and generating prompt information of compliance with laws and regulations, so as to prompt the approval end to approve and generate the approval result; If not, the non-compliant regulatory clauses will be listed and non-compliant prompt information will be generated to prompt the approval end to approve and generate the approval result.
4. The method for managing pharmaceutical enterprise documents as claimed in claim 3, It is characterized in that The approval end matches the corresponding regulatory clause information of each level according to the keywords, including: Constructing a semantic matching model and a database of regulatory clauses; wherein the semantic matching model includes keyword vectors corresponding to keywords and regulatory clause vectors; the regulatory clause data includes index information corresponding to each regulatory clause; Based on the semantic matching model, the similarity between the keyword vector and the regulatory clause vector is calculated; wherein the similarity calculation method includes: similarity represents the similarity; A represents the keyword vector; B represents the regulatory clause vector; A·B represents the dot product of the keyword vector and the regulatory clause vector; ‖A‖ and ‖B‖ represent the Euclidean norm of the keyword vector and the regulatory clause vector; The similarities are screened according to a preset threshold, and regulatory clause information of various levels matching the keywords is obtained through the regulatory clause database.
5. The method for managing pharmaceutical enterprise documents as claimed in claim 2, It is characterized in that The approval end approves the approval part, and further includes: Cutting the approval part into a plurality of grid units connected in sequence; and setting a membership function for each of the grid units; Monitor the mouse movement event, and obtain the current position of the mouse hovering according to the movement event; Calculating the center distance between the current position of the mouse and the geometric center of each of the grid cells; Calculating the membership value of each grid unit according to the center distance; According to the membership value, the fuzziness of the grid unit is set; and according to the fuzziness, the display effect of each grid unit is set.
6. The method for managing pharmaceutical enterprise documents as claimed in claim 5, It is characterized in that The calculation method of the center distance includes: Wherein, d represents the center distance; (x mouse -x center ) represents the current coordinates of the mouse; (y mouse -y center ) represents the coordinates of the geometric center of the grid cell.
7. The method for managing pharmaceutical enterprise documents as claimed in claim 5, It is characterized in that The calculation method of the membership value includes: Wherein, d represents the center distance; σ represents the control coefficient of the fuzziness; and e represents the membership value.
8. A management device for pharmaceutical enterprise documents, It is characterized in that include: A determination module is used for the server to obtain the pharmaceutical company document draft and the corresponding document information, and determine the corresponding approval process and approval node according to the document information, so that the approval end can approve the pharmaceutical company document draft according to the approval process based on the approval node; A receiving module, used for the server to receive the approval result of the approval end based on the approval node; The determination module is further configured to, if the approval result is approved, determine the corresponding training process and training unit according to the document information by the server, so as to train the training unit according to the training process; A generation module is used for the server to receive the training result information of the training unit, and convert the draft pharmaceutical enterprise document into a corresponding formal pharmaceutical enterprise document according to the training result information.
9. A management system for pharmaceutical company documents. It is characterized in that It includes a memory and a processor, wherein the memory stores a management program for pharmaceutical company documents, and the processor runs the management program for pharmaceutical company documents so that the management system for pharmaceutical company documents executes the management method for pharmaceutical company documents as described in any one of claims 1-7.
10. A computer-readable storage medium, It is characterized in that The computer-readable storage medium stores a pharmaceutical company document management program, and when the pharmaceutical company document management program is executed by the processor, the pharmaceutical company document management method according to any one of claims 1 to 7 is implemented.
Citation Information
Patent Citations
Multi-focus image file handling method
CN104700382A
Document management system on the basis of B / S configuration
CN105678435A
Method and device for intelligent approval
CN105719104A
Text review method and device, electronic equipment and computer storage medium
CN111046142A
Method and system for generating controlled file template of drug quality system
CN113177696A
Cited By
Medical laws and regulations and SOP compliance comparison method and system based on reference relation map
CN122346553A
